LZTS1的表达与乳腺癌化疗药物敏感性关系的研究

Association between the expression of LZTS1 and the chemosensitivity of breast cancer

目的探讨亮氨酸拉链肿瘤抑制基因1(leucine zipper tumor suppressor 1,LZTS1)与乳腺癌化疗药物敏感性的关系。方法对122例乳腺癌手术标本行体外胶滴包埋原代细胞培养药敏检测(collagen gel droplet-embedded culture-drug sensitivity test,CD-DST),检测分析LZTS1表达与化疗药物敏感性的关系。免疫组织化学检测278例经新辅助化疗的乳腺癌患者活检样本中LZTS1蛋白表达情况,分析其与临床病理特征的关系。观察LZTS1表达与化疗药物敏感性及化疗反应的关系。结果 122例乳腺癌中LZTS1表达与紫杉醇及长春瑞滨的化疗药物敏感性呈正相关(r=0.311,r=0.206;均P<0.05),与其他药物(表柔比星、氟尿嘧啶及顺铂)敏感性无相关性(r=0.121,r=0.083,r=0.017;均P>0.05)。Logistic回归分析显示,含紫杉醇方案(紫杉醇+多柔比星、紫杉醇+表柔比星或紫杉醇+表柔比星+环磷酰胺)化疗的乳腺癌患者的LZTS1表达情况可作为预测病理完全缓解的指标(P<0.01)。结论以紫杉醇为基础化疗方案的乳腺癌中,LZTS1可作为预测化疗反应的新指标。

Objective To investigate the relationship between leucine zipper tumor suppressor 1（ LZTS1） and breast cancer chemosensitivity. Methods Collagen gel droplet-embedded culture-drug sensitivity test（ CD-DST） was performed for 122 cases of breast cancer surgery samples,and the relationship between the expression of LZTS1 and cancer chemosensitivity was analyzed. The protein expression of LZTS1 in 278 biopsy samples of breast cancer after neoadjuvant chemotherapy was examined by immunohistochemical assay. The relationship between LZTS1 expression and chemotherapy response was further analyzed. Results The expression of LZTS1 in breast cancer patients was positively related to the sensitivity of paclitaxel and vinorelbine（ r = 0. 311,r = 0. 206; both P〈0. 05）,but was not significantly related to the sensitivity of epirubicin,5-fluorouracil and cisplatin（ r = 0. 121,r = 0. 083,r = 0. 010; all P〉0. 05）. Logistic regression analysis suggested that LZTS1 expression can predict the complete response rates of breast cancer patients after treatments of paclitaxel-based chemotherapies,including paclitaxel ＋ doxorubicin,paclitaxel ＋ epirubicin and paclitaxel ＋ epirubicin ＋ cyclophosphamide（ P〈0. 01）. Conclusion LZTS1 may be used as a marker to predict the response of breast cancer to paclitaxelbased chemotherapy.